



## PRIOR AUTHORIZATION POLICY

- POLICY:** Inflammatory Conditions – Ustekinumab Intravenous Products Prior Authorization Policy
- Stelara® (ustekinumab intravenous infusion – Janssen Biotech)
  - Imuldosa® (ustekinumab-srlf intravenous infusion – Accord)
  - Otulfi™ (ustekinumab-aauz intravenous infusion – Formycon/Fresenius)
  - Pyzchiva™ (ustekinumab-ttwe intravenous infusion – Sandoz/Samsung)
  - Selarsdi™ (ustekinumab-aekn intravenous infusion – Alvotech/Teva)
  - Starjemza™ (ustekinumab-hmny intravenous infusion – BioThera)
  - Steqeyma™ (ustekinumab-stba intravenous infusion – Celltrion)
  - Wezlana™ (ustekinumab-auub intravenous infusion – Amgen)
  - Yesintek™ (ustekinumab-kfce intravenous infusion – Biocon)
  - Ustekinumab intravenous infusion (Janssen Biotech)
  - Ustekinumab-ttwe intravenous infusion (Quallent)

**REVIEW DATE:** 04/22/2026

---

### **INSTRUCTIONS FOR USE**

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## **CIGNA NATIONAL FORMULARY COVERAGE:**

### **OVERVIEW**

Ustekinumab intravenous (IV), a monoclonal antibody against the p40 subunit of the interleukin (IL)-12 and IL-23 cytokines, is indicated for the following conditions:<sup>1,6-12,14</sup>

- **Crohn's disease** (CD), in adults and pediatric patients  $\geq 2$  years of age with moderate to severe active disease.
- **Ulcerative colitis** (UC), in adults with moderate to severe active disease.

In CD and UC, a single weight-based dose is administered by IV infusion. Following induction therapy with the IV product, the recommended maintenance dose is administered as a subcutaneous (SC) injection 8 weeks after the initial IV dose, then once every 8 weeks thereafter.

## Guidelines

Guidelines for the treatment of inflammatory conditions recommend use of ustekinumab.

- **Crohn's Disease:** The American College of Gastroenterology (ACG) [2025] and the American Gastroenterological Association (AGA) [2025] have guidelines for the management of CD in adults.<sup>2,13</sup> Both guidelines recommend upfront use of advanced therapies, rather than step-up therapy after failure of corticosteroids and/or immunomodulators. Advanced therapies recommended include tumor necrosis factor (TNF) inhibitors, Entyvio<sup>®</sup> (vedolizumab IV infusion, SC injection), IL-23 inhibitors, IL-12/23 inhibitors, and Rinvoq<sup>®</sup> (upadacitinib extended-release tablets).
- **Ulcerative Colitis:** The AGA (2024) and the ACG (2025) have clinical practice guidelines on the management of moderate to severe UC.<sup>3,4</sup> In moderate to severe disease, systemic corticosteroids or advanced therapies may be utilized for induction of remission. Advanced therapies recommended include TNF inhibitors, Entyvio, IL-23 inhibitors, IL-12/23 inhibitors, sphingosine-1-phosphate (S1P) receptor modulators, and Janus kinase (JAK) inhibitors. If steroids are utilized for induction, efforts should be made to introduce steroid-sparing agents for maintenance therapy. Of note, guidelines state corticosteroids may be avoided entirely when other effective induction strategies are planned.<sup>4</sup> Both guidelines also recommend that any drug that effectively treats induction should be continued for maintenance.

## POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of ustekinumab intravenous. Because of the specialized skills required for evaluation and diagnosis of patients treated with ustekinumab intravenous as well as the monitoring required for adverse events and long-term efficacy, approval requires ustekinumab intravenous to be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals are provided for 30 days, which is an adequate duration for the patient to receive one dose.

- **Stelara<sup>®</sup> (ustekinumab intravenous infusion – Janssen Biotech)**
- **Imuldosa<sup>®</sup> (ustekinumab-srlf intravenous infusion – Accord)**
- **Otulf<sup>™</sup> (ustekinumab-aauz intravenous infusion – Formycon/Fresenius)**

- **Pyzchiva™ (ustekinumab-ttwe intravenous infusion – Sandoz/Samsung)**
- **Selarsdi™ (ustekinumab-aekn intravenous infusion – Alvotech/Teva)**
- **Starjemza™ (ustekinumab-hmny intravenous infusion – BioThera)**
- **Steqeyma™ (ustekinumab-stba intravenous infusion – Celltrion)**
- **Wezlana™ (ustekinumab-auub intravenous infusion – Amgen)**
- **Yesintek™ (ustekinumab-kfce intravenous infusion – Biocon)**
- **Ustekinumab intravenous infusion (Janssen Biotech)**
- **Ustekinumab-ttwe intravenous infusion (Quallent)**

**is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

### **FDA-Approved Indications**

- 1. Crohn's Disease.** Approve a single dose if the patient meets ALL of the following (A, B, and C):
  - A) Patient is  $\geq$  2 years of age; AND**
  - B) The medication will be used as induction therapy; AND**
  - C) The medication is prescribed by or in consultation with a gastroenterologist.**
- 2. Ulcerative Colitis.** Approve a single dose if the patient meets ALL of the following (A, B, and C):
  - A) Patient is  $\geq$  18 years of age; AND**
  - B) The medication will be used as induction therapy; AND**
  - C) The medication is prescribed by or in consultation with a gastroenterologist.**

### **CONDITIONS NOT COVERED**

- **Stelara® (ustekinumab intravenous infusion – Janssen Biotech)**
- **Imuldosa® (ustekinumab-srlf intravenous infusion – Accord)**
- **Otulfi™ (ustekinumab-aaaz intravenous infusion – Formycon/Fresenius)**
- **Pyzchiva™ (ustekinumab-ttwe intravenous infusion – Sandoz/Samsung)**
- **Selarsdi™ (ustekinumab-aekn intravenous infusion – Alvotech/Teva)**
- **Starjemza™ (ustekinumab-hmny intravenous infusion – BioThera)**
- **Steqeyma™ (ustekinumab-stba intravenous infusion – Celltrion)**
- **Wezlana™ (ustekinumab-auub intravenous infusion – Amgen)**
- **Yesintek™ (ustekinumab-kfce intravenous infusion – Biocon)**
- **Ustekinumab intravenous infusion (Janssen Biotech)**
- **Ustekinumab-ttwe intravenous infusion (Quallent)**

**is(are) considered not medically necessary for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):**

- 1. Ankylosing Spondylitis (AS).** There are other biologic therapies indicated in AS. More data are needed to demonstrate efficacy of ustekinumab in this

condition. There is a published proof-of-concept trial evaluating ustekinumab in AS (TOPAS – UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis).<sup>4</sup> TOPAS was a prospective, open-label study evaluating ustekinumab 90 mg subcutaneous at Week 0, 4, and 16 in patients (n = 20) with AS. After Week 16, patients were followed through Week 28. Patients who previously failed to respond to tumor necrosis factor inhibitor (TNFi) were excluded. The primary endpoint was a 40% improvement in disease activity at Week 24 according to the Assessment of SpondyloArthritis International Society (ASAS) criteria (ASAS40) in the intent-to-treat population which included all patients who received at least one dose of ustekinumab. In all, 65% of patients (95% confidence interval [CI]: 41%, 85%; n = 13/20) achieved an ASAS40 response at Week 24. There was at least a 50% improvement of the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) achieved by 55% of patients (95% CI: 32%, 77%; n = 11/20). However, enthesitis (measured by MASES [Maastricht AS Entheses Score] and SPARCC [SPondyloArthritis Research Consortium of Canada] enthesitis indices) and the number of swollen joints were not significantly improved at Week 24. There was a significant reduction of active inflammation on magnetic resonance imaging at Week 24 compared with baseline in sacroiliac joints.

**2. Concurrent Use with a Biologic or with a Targeted Synthetic Oral Small Molecule Drug.** This medication should not be administered in combination with another biologic or with a targeted synthetic oral small molecule drug used for an inflammatory condition (see [Appendix](#) for examples). Combination therapy is generally not recommended due to a potentially higher rate of adverse events and lack of controlled clinical data supporting additive efficacy.

Note: This does NOT exclude the use of conventional synthetic DMARDs (e.g., methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine) in combination with this medication.

**3. Plaque Psoriasis.** Ustekinumab for subcutaneous injection is indicated for treatment of plaque psoriasis.<sup>1</sup> Appropriate dosing of ustekinumab intravenous in plaque psoriasis is unclear.

**4. Psoriatic Arthritis.** Ustekinumab for subcutaneous injection is indicated for treatment of psoriatic arthritis.<sup>1</sup> Appropriate dosing of ustekinumab intravenous in psoriatic arthritis is unclear.

## REFERENCES

1. Stelara® intravenous infusion, subcutaneous injection [prescribing information]. Horsham, PA: Janssen Biotech; April 2026.
2. Lichtenstein G, Loftus E, Afzali A, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol.* 2025 June;120(6):1225-1264.
3. Singh S, Loftus EV Jr, Limketkai BN, et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. *Gastroenterology.* 2024 Dec;167(7):1307-1343.
4. Rubin D, Ananthakrishnan A, Siegel C. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. *Am J of Gastroenterol.* 2025 June;120(6):1187-1224.
5. Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). *Ann Rheum Dis.* 2014;73(5):817-823.

6. Otulfi® intravenous infusion, subcutaneous injection [prescribing information]. Lake Zurich, IL: Fresenius; December 2024.
7. Pyzchiva® intravenous infusion, subcutaneous injection [prescribing information]. Princeton, NJ: Sandoz; June 2024.
8. Selarsdi® intravenous infusion, subcutaneous injection [prescribing information]. Parsippany, NJ: Teva; October 2024.
9. Steqeyma® intravenous infusion, subcutaneous injection [prescribing information]. Incheon, Republic of Korea: Celltrion; December 2024.
10. Yesintek® intravenous infusion, subcutaneous injection [prescribing information]. Cambridge, MA: Biocon; December 2024.
11. Wezlana® intravenous infusion, subcutaneous injection [prescribing information]. Thousand Oaks, CA: Amgen; January 2025.
12. Imuldosa® intravenous infusion, subcutaneous injection [prescribing information]. Raleigh, NC: Accord; October 2025.
13. Scott FI, Ananthakrishnan AN, Click B, et al. AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease. *Gastroenterology*. 2025 Dec;169(7):1397-1448.
14. Starjemza™ intravenous infusion, subcutaneous injection [prescribing information]. Guangzhou, Guang dong, China: Bio-Thera; May 2025.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	<b>Ulcerative Colitis:</b> A note was added that a trial of a mesalamine product does not count as a systemic agent for ulcerative colitis.	07/24/2024
Selected Revision	<b>Conditions Not Covered</b> : Concurrent use with a Biologic or with a Targeted Synthetic Oral Small Molecule Drug was changed to as listed (previously oral small molecule drug was listed as Disease-Modifying Antirheumatic Drug).	09/11/2024
Selected Revision	Policy name was changed to more generally list Ustekinumab Intravenous Products; previously policy was specific to Stelara Intravenous. Wezlana intravenous was added to the policy; the same criteria apply for Wezlana and for Stelara intravenous.	12/18/2024

## HISTORY (CONTINUED)

Type of Revision	Summary of Changes	Review Date
Selected Revision	Otulfi, Pyzchiva, Selarsdi, Steqeyma, and Yesintek intravenous were added to the policy; the same criteria apply for all ustekinumab intravenous products.	01/29/2025
Selected Revision	Ustekinumab-ttwe intravenous was added to the policy; the same criteria apply as the other ustekinumab intravenous products.	02/19/2025
Selected Revision	Ustekinumab intravenous (unbranded Stelara) was added to the policy; the same criteria apply as the other ustekinumab intravenous products.	04/23/2025
Selected Revision	Imuldosa intravenous was added to the policy; the same criteria apply for all ustekinumab intravenous products.	06/25/2025
Annual Revision	<b>Ulcerative Colitis:</b> Removed the following options of approval: (1) the patient has tried one systemic therapy; (2) the patient has pouchitis and tried an antibiotic, probiotic, corticosteroid enema, or mesalamine enema.	07/23/2025
Selected Revision	Starjemza intravenous was added to the policy; the same criteria apply as the other ustekinumab intravenous products.	11/05/2025
Selected Revision	<b>Crohn's Disease:</b> For initial therapy, the following options of approval were removed: The patient has tried or is currently	02/11/2026

	taking systemic corticosteroids, or corticosteroids are contraindicated; patient has tried one conventional systemic therapy for Crohn's disease along with the associated Note; patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas; patient had ileocolonic resection (to reduce the chance of Crohn's disease recurrence). <b>Appendix:</b> Otezla XR (apremilast extended-release tablets) was added.	
Early Annual Revision	<b>Crohn's Disease:</b> The age requirement was modified from $\geq 18$ years to $\geq 2$ years of age.	04/22/2026

## APPENDIX

	Mechanism of Action	Examples of Indications*
<b>Biologics</b>		
<b>Adalimumab SC Products</b> (Humira®, biosimilars)	Inhibition of TNF	AS, CD, HS, JIA, PsO, PsA, RA, UC
<b>Cimzia</b> ® (certolizumab pegol SC injection)	Inhibition of TNF	AS, CD, JIA, nr-axSpA, PsO, PsA, RA
<b>Etanercept SC Products</b> (Enbrel®, biosimilars)	Inhibition of TNF	AS, JIA, PsO, PsA, RA
<b>Infliximab IV Products</b> (Remicade®, biosimilars)	Inhibition of TNF	AS, CD, PsO, PsA, RA, UC
<b>Zymfentra</b> ® (infliximab-dyyb SC injection)	Inhibition of TNF	CD, UC
<b>Simponi</b> ®, <b>Simponi Aria</b> ® (golimumab SC injection, golimumab IV infusion)	Inhibition of TNF	SC formulation: AS, PsA, RA, UC
		IV formulation: AS, PJIA, PsA, RA
<b>Kineret</b> ® (anakinra SC injection)	Inhibition of IL-1	RA
<b>Tocilizumab Products</b> (Actemra® IV, biosimilars; Actemra SC, biosimilars)	Inhibition of IL-6	SC formulation: PJIA, RA, SJIA
		IV formulation: PJIA, RA, SJIA
<b>Kevzara</b> ® (sarilumab SC injection)	Inhibition of IL-6	PJIA, RA
<b>Siliq</b> ® (brodalumab SC injection)	Inhibition of IL-17	PsO
<b>Cosentyx</b> ® (secukinumab SC injection; secukinumab IV infusion)	Inhibition of IL-17A	SC formulation: AS, ERA, HS, nr-axSpA, PsO, PsA
		IV formulation: AS, nr-axSpA, PsA
<b>Taltz</b> ® (ixekizumab SC injection)	Inhibition of IL-17A	AS, nr-axSpA, PsO, PsA
<b>Bimzelx</b> ® (bimekizumab-bkzx SC injection)	Inhibition of IL-17A/17F	AS, HS, nr-axSpA, PsO, PsA
<b>Ustekinumab Products</b> (Stelara® IV, biosimilars; Stelara SC, biosimilars)	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC
		IV formulation: CD, UC
<b>Ilumya</b> ® (tildrakizumab-asmn SC injection)	Inhibition of IL-23	PsO
<b>OmvoH</b> ® (mirikizumab IV infusion, SC injection)	Inhibition of IL-23	CD, UC
<b>Skyrizi</b> ® (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion)	Inhibition of IL-23	SC formulation: CD, PsO, PsA, UC
		IV formulation: CD, UC
<b>Tremfya</b> ® (guselkumab SC injection, guselkumab IV infusion)	Inhibition of IL-23	SC formulation: CD, PsO, PsA, UC
		IV formulation: CD, UC
<b>Entyvio</b> ® (vedolizumab IV infusion, vedolizumab SC injection)	Integrin receptor antagonist	CD, UC

<b>Orencia</b> ® (abatacept IV infusion, abatacept SC injection)	T-cell costimulation modulator	SC formulation: JIA, PsA, RA IV formulation: JIA, PsA, RA
<b>Rituximab IV Products</b> (Rituxan®, biosimilars)	CD20-directed antibody	RA
<b>Oral Therapies/Targeted Synthetic Oral Small Molecule Drugs</b>		
<b>Otezla</b> ® (apremilast tablets)	Inhibition of PDE4	PsO, PsA
<b>Otezla</b> ® <b>XR</b> (apremilast extended-release tablets)	Inhibition of PDE4	PsO, PsA
<b>Sotyktu</b> ® (deucravacitinib tablets)	Inhibition of TYK2	PsO, PsA
<b>Cibinqo</b> ™ (abrocitinib tablets)	Inhibition of JAK pathways	AD
<b>Olumiant</b> ® (baricitinib tablets)	Inhibition of JAK pathways	AA, RA
<b>Litfulo</b> ® (ritlecitinib capsules)	Inhibition of JAK pathways	AA
<b>Leqselvi</b> ® (deuruxolitinib tablets)	Inhibition of JAK pathways	AA
<b>Rinvoq</b> ® (upadacitinib extended-release tablets)	Inhibition of JAK pathways	AD, AS, CD, nr-axSpA, PJIA, PsA, RA, UC
<b>Rinvoq</b> ® <b>LQ</b> (upadacitinib oral solution)	Inhibition of JAK pathways	PsA, PJIA
<b>Xeljanz</b> ® (tofacitinib tablets/oral solution)	Inhibition of JAK pathways	Tablets: AS, PsA, RA, UC Oral solution: PJIA, PsA
<b>Xeljanz</b> ® <b>XR</b> (tofacitinib extended-release tablets)	Inhibition of JAK pathways	AS, PsA, RA, UC
<b>Zeposia</b> ® (ozanimod tablets)	Sphingosine 1 phosphate receptor modulator	UC
<b>Velsipity</b> ® (etrasimod tablets)	Sphingosine 1 phosphate receptor modulator	UC

\* Not an all-inclusive list of indications. Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; AS – Ankylosing spondylitis; CD – Crohn’s disease; HS – Hidradenitis Suppurativa; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; IV – Intravenous, PJIA – Polyarticular juvenile idiopathic arthritis; IL – Interleukin; SJIA – Systemic juvenile idiopathic arthritis; ERA – Enthesitis-related arthritis; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AD – Atopic dermatitis; AA – Alopecia areata; TYK2 – Tyrosine kinase 2.

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.